Hyperlipidemia Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Hyperlipidemia 
Drugs Market Research 
and Forecast Report 
2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A cc o r d i ng  t o  t h e  l a t es t  r e p o r t  b y  I M A R C  G r o up ,  t i t l e d  " H y p e r l i p id e m ia  D r u g s  Ma r k e t :  
G l o b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  Gr o w th ,  O p p o r t u n i t y  a n d  F o r e c as t  2 0 2 4 -
20 3 2 , "  t h e  g l o b a l  h y p e r l i p i d e m i a  d r u g s  m a r ke t  s i z e  r e a c he d  U S $  2 2 . 7  B i l l i o n  i n  2 0 2 3 .
H yp e r l i p i d em i a  r e f e r s  t o  a  c o n d i t i o n  t ha t  c a u se s  a b n o r m a l l y  h i gh  l e v e l s  o f  f a t s  o r  l i p i d s  
i n  t h e  b l o o d .  I t  i s  a  co m m on  t yp e  o f  d y s l i p i d e m i a  t h a t  c a n  b e  i n h e r i t ed  o r  re s u l t  f r o m  a n  
Report un h e a l t h y  l i f e s t y l e  an d  p o o r  d i e t .  T h e  d i so r d e r  ma y  l e a d  to  c a r d i a c  s t r o k e ,  p e r i p h e ra l  
va s c u l a r  d i s e as e s ,  o b e s i t y ,  h y p e r t e n s i o n ,  an d  ca r d i o v as c u l a r  d i s o r d e r s ( C V D s ) .  
H yp e r l i p i d em i a  c a n  b e  d e t e c t ed  b y  p e r f o r m i n g  a  b l o o d  t es t  c a l l e d  a  l i p i d  p a n e l  o r  l i p i d  
Highlight and p r o f i l e .  
S ta t i n s  a re  t h e  p r i ma r y  l i ne  o f  t r e a t m en t  i n  s e c on d a r y  hy p e r l i p i de m i a  c a u s e d  b y  a n  
Description un h e a l t h y  l i f e s t y l e .  S o m e  o f  t he  o t h e r  c o mm o n  d r u g s  u s e d  i n  t h e  t r e a t me n t  o f  hy p e r l i p i de m i a  a re  b i l e  a c i d  s e qu e s t ra n t s ,  P C S K 9 ,  a n d  m i sc e l l a n eo u s  
an t i h y p e r l i p i d e m i c  a g e n ts ,  w h i ch  h e l p  re d u c e  t h e  p r od u c t i o n  o f  c ho l e s t e ro l  i n  t he  l i v e r .  
T he y  a l s o  l o w e r  t h e  n u mb e r  o f  l i p i d s  i n  t h e  b l o o d s t r e a m  a nd  r e d u c e  i n f l a m ma t i o n  a n d  
da m a g e  d o n e  t o  t h e  c e l l s .
R eq u e s t  f o r  a  P D F  sa m p le  o f  th i s  r ep o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / h yp e r l i p i de m i a - d r u g s - ma r k e t / r e q u es t s a mp l e
Report Description
Global  Hyper l ip idemia Drugs Market Trends:
The g loba l  hyper l ip idemia drugs market  is  pr imar i ly  dr iven by the increas ing awareness regard ing the 
assoc iated r isks  of  CVDs and h igh cholestero l .  Governments are in t roduc ing new gu ide l ines redef in ing 
at - r isk  pat ient  groups and recommending the use of  ant i -hyper l ip idemic to  lower the r isk  o f  these 
d iseases.  In  add i t ion to th is ,  the upcoming patent  expi rat ion has resu l ted in  the gener ic iza t ion of  s tat in  
and cholestero l  absorpt ion inhib i tors ,  wh ich is  s igni f icant ly  augment ing the market  growth.  
Fur thermore,  the launch of  innovat ive  products ,  such as the development  of  novel  drugs,  which of fer  
improved e f f icacy and safety  prof i le ,  i s  pos i t ive ly  impact ing the market  across the g lobe.  Moreover ,  
there has  been extens ive research and deve lopment  (R&D) act iv i t ies  for  developing innovat ive drugs.
View Report  TOC, Figures and Tables :  ht tps: / /www.imarcgroup.com/hyper l ip idemia-drugs-market
Breakup by Drug Type:
• Stat ins
• Bile Acid Sequestrants
• Cholesterol  Absorpt ion Inhibitors
• PCSK9 Inhibitors
• Others
Report 
Segmentation Breakup by End User:
• Hospitals
• Clinics
• Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
Report • Middle East and Afr ica
Segmentation
• Amgen Inc.
• AstraZeneca PLC
• Dai ichi Sankyo Company Limited
•
Competitive El i  Li l ly and Company
• Esperion Therapeutics Inc.
Landscape • GlaxoSmithKl ine Pharmaceuticals Limited 
with Key (GlaxoSmithKl ine Plc)
• Immuron Limited
Players • Ionis Pharmaceuticals Inc.
• Merck & Co. Inc.
• Pfi zer Inc.
• Sanofi  S.A.
What was the size of the global hyperlipidemia 
drugs market in 2023?
What is the expected growth rate of the global 
hyperlipidemia drugs market during 2024-2032?
What are the key factors driving the global 
Key hyperlipidemia drugs market?
Questions What has been the impact of COVID-19 on the 
global hyperlipidemia drugs market?
Answered in 
What is the breakup of the global hyperlipidemia 
the Report drugs market based on the drug type?
What is the breakup of the global hyperlipidemia 
drugs market based on the end user?
What are the key regions in the global 
hyperlipidemia drugs market?
Who are the key players/companies in the global 
hyperlipidemia drugs market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  H y p e r l i p i d e m i a  D r u g s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  D r u g  T y p e
    6 . 1     S t a t i n s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     B i l e  A c i d  S e q u e s t r a n t s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     C h o l e s t e r o l  A b s o r p t i o n  I n h i b i t o r s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     P C S K 9  I n h i b i t o r s
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     O t h e r s
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  E n d  U s e r
    7 . 1     H o s p i t a l s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
Table of     7 . 2     C l i n i c s        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O t h e r s
Contents         7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  R e g i o n
    8 . 1     N o r t h  A m e r i c a
        8 . 1 . 1  U n i t e d  S t a t e s
           8 . 1 . 1 . 1  M a r k e t  T r e n d s
           8 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        8 . 1 . 2  C a n a d a
           8 . 1 . 2 . 1  M a r k e t  T r e n d s
           8 . 1 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 2     A s i a  P a c i f i c
        8 . 2 . 1  C h i n a
           8 . 2 . 1 . 1  M a r k e t  T r e n d s
           8 . 2 . 1 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /h yp e r l i p i d em ia -d rugs -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: